As we learn more about the biology of cancer, we may be able to apply prognostic biomarkers to select patients at high risk or low risk of disease recurrence or progression. This will allow a priori stratification of patients in clinical trials and will help to tailor treatment to patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schmoll, H. J. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 23, 2479–2516 (2012).
La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587–596 (2011).
Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261–1270 (2011).
Salazar, R. et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 1, 17–24 (2011).
Gray, R. G. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 29, 4611–4619 (2011).
Huijbers, A. et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann. Oncol. 24, 179–185 (2013).
Domingo, E. et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J. Pathol. 229, 441–448 (2013).
Kerr, D. J. & Midgley, R. Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J. Clin. Oncol. 28, 3210–3212 (2010).
Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer 34, 585–612 (1976).
Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117–3125 (2009).
Acknowledgements
The authors thank Ian Tomlinson, Nicholas B. La Thangue and Rachel Midgley for valuable scientific discussions while writing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. J. Kerr has received educational grants and speakers honorarium from Genomic Health and is a Director of Oxford Cancer Biomarkers. Y. Shi declares no competing interests.
Rights and permissions
About this article
Cite this article
Kerr, D., Shi, Y. Tailoring treatment and trials to prognosis. Nat Rev Clin Oncol 10, 429–430 (2013). https://doi.org/10.1038/nrclinonc.2013.97
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.97
